Display options
Cite
Hartl BA, Hirschberg H, Marcu L, et al. Characterizing low fluence thresholds for in vitro photodynamic therapy. Biomed Opt Express. 2015;6(3):770-9doi: 10.1364/BOE.6.000770.
Hartl, B. A., Hirschberg, H., Marcu, L., & Cherry, S. R. (2015). Characterizing low fluence thresholds for in vitro photodynamic therapy. Biomedical optics express, 6(3), 770-9. https://doi.org/10.1364/BOE.6.000770
Hartl, Brad A, et al. "Characterizing low fluence thresholds for in vitro photodynamic therapy." Biomedical optics express vol. 6,3 (2015): 770-9. doi: https://doi.org/10.1364/BOE.6.000770
Hartl BA, Hirschberg H, Marcu L, Cherry SR. Characterizing low fluence thresholds for in vitro photodynamic therapy. Biomed Opt Express. 2015 Feb 10;6(3):770-9. doi: 10.1364/BOE.6.000770. eCollection 2015 Mar 01. PMID: 25798302; PMCID: PMC4361432.
Copy Download .nbib Format: NLM
Share it on

Biomed Opt Express. 2015 Feb 10;6(3):770-9. doi: 10.1364/BOE.6.000770. eCollection 2015 Mar 01.

Characterizing low fluence thresholds for in vitro photodynamic therapy.

Biomedical optics express

Brad A Hartl, Henry Hirschberg, Laura Marcu, Simon R Cherry

Affiliations

  1. Department of Biomedical Engineering, University of California, Davis, Davis, CA 95616, USA.
  2. Beckman Laser Institute and Medical Clinic, University of California, Irvine, Irvine, CA 92697, USA.

PMID: 25798302 PMCID: PMC4361432 DOI: 10.1364/BOE.6.000770

Abstract

The translation of photodynamic therapy (PDT) to the clinic has mostly been limited to superficial diseases where traditional light delivery is noninvasive. To overcome this limitation, a variety of mechanisms have been suggested to noninvasively deliver light to deep tissues. This work explores the minimum amount of light required by these methods to produce a meaningful PDT effect in the in vitro setting under representative low fluence and wavelength conditions. This threshold was found to be around 192 mJ/cm(2) using the clinically approved photosensitizer aminolevulinic acid and 12 mJ/cm(2) for the more efficient, second generation photosensitizer TPPS2a.

Keywords: (170.0170) Medical optics and biotechnology; (170.5180) Photodynamic therapy

References

  1. J Biol Chem. 2005 Jun 3;280(22):21061-6 - PubMed
  2. Photochem Photobiol. 2012 May-Jun;88(3):512-22 - PubMed
  3. Photodermatol Photoimmunol Photomed. 2010 Jun;26(3):118-32 - PubMed
  4. CA Cancer J Clin. 2011 Jul-Aug;61(4):250-81 - PubMed
  5. Br J Cancer. 2006 Jul 17;95(2):189-96 - PubMed
  6. J Photochem Photobiol B. 2007 Sep 25;88(2-3):156-62 - PubMed
  7. J Nanosci Nanotechnol. 2006 Apr;6(4):1159-66 - PubMed
  8. Nat Med. 2012 Oct;18(10):1580-5 - PubMed
  9. Lasers Surg Med. 2009 Oct;41(8):578-84 - PubMed
  10. Photochem Photobiol. 2004 Jul-Aug;80:22-30 - PubMed
  11. Technol Cancer Res Treat. 2008 Aug;7(4):309-20 - PubMed
  12. Phys Med Biol. 2009 Aug 21;54(16):N355-65 - PubMed
  13. Proc SPIE Int Soc Opt Eng. 2013 Jul 13;7380:73801W - PubMed
  14. Viruses. 2012 Jul;4(7):1034-74 - PubMed
  15. Org Biomol Chem. 2011 Sep 7;9(17):6004-10 - PubMed
  16. Angew Chem Int Ed Engl. 2011 Jun 20;50(26):5808-29 - PubMed
  17. Oncol Rep. 2013 Mar;29(3):911-6 - PubMed
  18. Lasers Surg Med. 2006 Jun;38(5):489-93 - PubMed
  19. Semin Ophthalmol. 2001 Dec;16(4):201-6 - PubMed
  20. Nanomedicine (Lond). 2014 Oct;9(15):2339-51 - PubMed
  21. Biomed Mater Eng. 2008;18(4-5):319-27 - PubMed
  22. Phys Med Biol. 2008 May 7;53(9):R61-109 - PubMed

Publication Types

Grant support